Urogen Pharma Ltd (URGN)

$5.14 +0.22 (4.47%)
Market Cap 226.85M
Revenue (ttm) 90.40M
Net Income (ttm) -126.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -140.34%
Debt to Equity Ratio -2.63
Volume 1,478,900
Avg Vol 1,513,984
Day's Range N/A - N/A
Shares Out 46.11M
Stochastic %K 87%
Beta 0.40
Analysts Strong Sell
Price Target $20.29

Latest News on URGN

Shareholders who lost money on UroGen Pharma Ltd. (NASDAQ: URGN) Should Contact Wolf Haldenstein

Jun 5, 2025, 9:31 AM EDT - 14 hours ago

Shareholders who lost money on UroGen Pharma Ltd. (NASDAQ: URGN) Should Contact Wolf Haldenstein

URGN LAWSUIT: UroGen Pharma Ltd. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

Jun 4, 2025, 3:46 PM EDT - 1 day ago

URGN LAWSUIT: UroGen Pharma Ltd. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

URGN STOCK NOTICE: UroGen Pharma Ltd. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 28 Legal Deadline

Jun 3, 2025, 3:33 PM EDT - 2 days ago

URGN STOCK NOTICE: UroGen Pharma Ltd. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 28 Legal Deadline

Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action

Jun 3, 2025, 12:19 PM EDT - 2 days ago

Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Shareholders to Reach Out

Jun 3, 2025, 10:00 AM EDT - 2 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Shareholders to Reach Out

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

Jun 2, 2025, 11:00 AM EDT - 3 days ago

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Shareholders to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 3 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Shareholders to Learn More About the Investigation

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Jun 2, 2025, 10:00 AM EDT - 3 days ago

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 4 days ago

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Shareholders to Inquire about Securities Investigation

May 30, 2025, 10:00 AM EDT - 6 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Shareholders to Inquire about Securities Investigation

Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd.

May 29, 2025, 3:00 PM EDT - 7 days ago

Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd.

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman

May 29, 2025, 1:45 PM EDT - 7 days ago

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny - Hagens Berman

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 10:00 AM EDT - 7 days ago

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma Ltd. (URGN) And Encourages Investors to Connect

May 28, 2025, 10:00 AM EDT - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating UroGen Pharma Ltd. (URGN) And Encourages Investors to Connect

Did UroGen Pharma Ltd. (URGN) Mislead Investors?

May 28, 2025, 9:15 AM EDT - 8 days ago

Did UroGen Pharma Ltd. (URGN) Mislead Investors?

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 27, 2025, 4:00 PM EDT - 9 days ago

UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman

May 27, 2025, 3:14 PM EDT - 9 days ago

UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor Scrutiny – Hagens Berman

Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Stockholders to Inquire about Securities Investigation

May 27, 2025, 10:00 AM EDT - 9 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages UroGen Pharma Ltd. (URGN) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Investors to Learn More About the Investigation

May 26, 2025, 10:00 AM EDT - 10 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Investors to Learn More About the Investigation

UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug

May 25, 2025, 2:16 PM EDT - 11 days ago

UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 13 days ago

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Stockholders to Learn More About the Investigation

May 22, 2025, 10:00 AM EDT - 14 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Stockholders to Learn More About the Investigation

UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either

May 21, 2025, 3:10 PM EDT - 15 days ago

UroGen Pharma: ODAC Decision Puts Drug Approval In Limbo, But It's Not Over, Either